Penserra Capital Management LLC Precision Biosciences Inc Transaction History

Penserra Capital Management LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.34 - $0.69 $27,182 - $55,164	-79,949 Reduced 59.81%	53,712 $18,000
Q2 2023 Aug 11, 2023	BUY	$0.52 - $0.91 $22,038 - $38,566	42,381 Added 46.43%	133,661 $70,000
Q1 2023 Apr 24, 2023	BUY	$0.7 - $1.41 $4,669 - $9,404	6,670 Added 7.88%	91,280 $68,000
Q4 2022 Feb 13, 2023	SELL	$0.97 - $45.0 $13,158 - $610,425	-13,565 Reduced 13.82%	84,610 $100,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $40.8 $98,506 - $3.29 Million	80,743 Added 463.19%	98,175 $127,000
Q2 2022 Aug 15, 2022	BUY	$1.15 - $3.34 $2,033 - $5,905	1,768 Added 11.29%	17,432 $27,000
Q1 2022 May 13, 2022	BUY	$2.96 - $7.76 $46,365 - $121,552	15,664 New	15,664 $48,000
Q4 2021 Feb 15, 2022	SELL	$7.4 - $11.66 $10,064 - $15,857	-1,360 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$9.18 - $14.15 $459 - $707	50 Added 3.82%	1,360 $15,000
Q2 2021 Aug 12, 2021	BUY	$8.07 - $12.52 $968 - $1,502	120 Added 10.08%	1,310 $16,000
Q1 2021 May 13, 2021	SELL	$8.57 - $15.79 $128 - $236	-15 Reduced 1.24%	1,190 $12,000
Q4 2020 Feb 12, 2021	BUY	$5.98 - $12.47 $4,538 - $9,464	759 Added 170.18%	1,205 $10,000
Q3 2020 Nov 13, 2020	BUY	$4.65 - $8.73 $2,073 - $3,893	446 New	446 $2,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $554M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.